HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Managing Brain Metastases in Breast Cancer

February 25th 2015

Role of T-DM1 in HER2-Positive Breast Cancer

February 25th 2015

Pertuzumab in HER2-Positive Metastatic Breast Cancer

February 25th 2015

BOLERO-2: Everolimus Plus Exemestane in Resistant MBC

February 25th 2015

Role of Bevacizumab in Breast Cancer

February 25th 2015

Endocrine Therapy Resistance in Breast Cancer

February 25th 2015

CDK4/6 Inhibition in Metastatic Breast Cancer

February 25th 2015

Treating ER-Positive De Novo Metastatic Breast Cancer

February 25th 2015

Genetic Tests Offer New Tool for Tumor Assessment

February 25th 2015

Pathology, Oncology Collaboration in Breast Cancer

February 25th 2015

Predicting Risk of Recurrence in Breast Cancer

February 25th 2015

Reviewing Key Genomic Assays in Breast Cancer

February 25th 2015

Pathologist's Role in Genetic Testing for Breast Cancer

February 25th 2015

Role of Genetic Testing in Breast Cancer

February 25th 2015

Introduction: Impact of Molecular Subtyping in Breast Cancer

February 25th 2015

Dr. Edith Perez on BOLERO-1 Results in HER2-Positive Breast Cancer

February 24th 2015

Edith Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, compares the results of the BOLERO-1 and BOLERO-3 trials.

Swain Discusses Final Survival Analysis of CLEOPATRA Study

February 24th 2015

For additional insight on the CLEOPATRA trial and its implications for clinical practice, OncLive interviewed Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center.

Unprecedented OS Benefit Cements Pertuzumab Regimen as Frontline Standard in HER2-Positive MBC

February 20th 2015

Frontline pertuzumab plus trastuzumab and docetaxel improved survival by nearly 16 months in metastatic HER2-positive breast cancer, according to results from the phase III CLEOPATRA study that are now published in The New England Journal of Medicine.

Finn Discusses Clinical Implications of Palbociclib Approval for MBC

February 10th 2015

For further insight on the significance of palbociclib's approval, OncLive sat down with the lead investigator of PALOMA-1, Richard Finn, MD, from the Jonsson Comprehensive Cancer Center at UCLA.

Lackluster T-DM1 Results Surprise Perez

December 22nd 2014

Researchers will dissect topline results from the MARIANNE trial in the coming weeks in an effort to understand why T-DM1 (ado-trastuzumab emtansine; Kadcyla) failed to triumph as a first-line treatment in the metastatic setting for patients with advanced HER2-positive breast cancer despite the promise of earlier findings